Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells
- Author(s)
- Bidur Parajuli; Hyun-Gyo Lee; Sang-Hoon Kwon; Soon-Do Cha; So-Jin Shin; Gun-Ho Lee; Insoo Bae; Chi-Heum Cho
- Keimyung Author(s)
- Kwon, Sang Hoon; Cha, Soon Do; Shin, So Jin; Cho, Chi Heum
- Department
- Dept. of Obstetrics & Gynecology (산부인과학)
Institute for Cancer Research (암연구소)
Institute for Medical Science (의과학연구소)
- Journal Title
- Cancer Epidemiology
- Issued Date
- 2013
- Volume
- 37
- Issue
- 4
- Abstract
- Background: Despite advances in treatment, ovarian cancer is the most lethal gynecologic malignancy. Therefore significant efforts are being made to develop novel strategies for the treatment of ovarian cancer. Salinomycin has been shown to be highly effective in the elimination of cancer stem cells both in vitro and in vivo. The present study focused on investigating important cell signaling molecules such as Akt and NF-κB during salinomycin-induced apoptosis in cisplatin resistant ovarian cancer cells (A2780cis).
Methods: MTT assay was performed to determine cell viability. Flow cytometry and DNA fragmentation assay were performed to analyze the effect on cell cycle and apoptosis. The expression of apoptosis related proteins was evaluated by Western blot analysis.
Results: The cell viability was significantly reduced by salinomycin treatment in a dose dependent manner. The flow cytometry result showed an increase in sub-G1 phase. Salinomycin inhibited the nuclear transportation of NF-κB, and downregulated Akt expression. Declined Bcl-2, activation of caspase-3 and increased PARP cleavage triggered apoptosis. Moreover, DNA fragmentation assay also revealed apoptotic induction.
Conclusion: The result suggested that salinomycin-induced apoptosis in A2780cis was associated with inhibition of Akt/NF-κB. It may become a potential chemotherapeutic agent for the cisplatin resistant ovarian cancer therapy.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.